Harrow, Inc. $HROW Shares Purchased by American Century Companies Inc.

Key Points

• American Century Companies Inc. has increased its stake in Harrow, Inc. by 69.9% during the first quarter, now holding 44,104 shares valued at approximately $1.17 million.
• Multiple analysts have given Harrow a rating of "Buy" with an average price target of $64.67, reflecting positive sentiment in the market.
• Harrow reported earnings of $0.24 EPS for the last quarter, significantly exceeding analyst expectations of $0.01 EPS, despite facing a negative net margin.

American Century Companies Inc. raised its stake in Harrow, Inc. (NASDAQ:HROW - Free Report) by 69.9% in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 44,104 shares of the company's stock after purchasing an additional 18,142 shares during the quarter. American Century Companies Inc. owned 0.12% of Harrow worth $1,173,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also bought and sold shares of the company. Fox Run Management L.L.C. purchased a new position in Harrow in the first quarter valued at about $282,000. HighTower Advisors LLC increased its holdings in shares of Harrow by 30.5% in the 1st quarter. HighTower Advisors LLC now owns 13,217 shares of the company's stock worth $352,000 after buying an additional 3,090 shares during the last quarter. Nuveen LLC purchased a new position in shares of Harrow during the 1st quarter valued at about $2,046,000. Equitable Trust Co. boosted its stake in shares of Harrow by 9.2% in the 1st quarter. Equitable Trust Co. now owns 47,570 shares of the company's stock valued at $1,265,000 after purchasing an additional 4,015 shares in the last quarter. Finally, Royce & Associates LP lifted its stake in shares of Harrow by 12.0% in the 1st quarter. Royce & Associates LP now owns 327,096 shares of the company's stock valued at $8,701,000 after acquiring an additional 35,006 shares during the last quarter. Institutional investors own 72.76% of the company's stock.

Harrow Stock Performance

HROW traded up $2.91 on Monday, reaching $39.90. 524,658 shares of the stock were exchanged, compared to its average volume of 480,030. Harrow, Inc. has a fifty-two week low of $20.85 and a fifty-two week high of $59.23. The company's 50-day moving average price is $35.29 and its 200 day moving average price is $29.64. The company has a debt-to-equity ratio of 0.78, a current ratio of 0.62 and a quick ratio of 0.58. The firm has a market capitalization of $1.48 billion, a PE ratio of -160.42 and a beta of 0.33.

Harrow (NASDAQ:HROW - Get Free Report) last posted its quarterly earnings results on Monday, August 11th. The company reported $0.24 earnings per share for the quarter, topping the consensus estimate of $0.01 by $0.23. The firm had revenue of $63.74 million for the quarter, compared to the consensus estimate of $64.23 million. Harrow had a negative net margin of 4.49% and a negative return on equity of 2.18%. Harrow has set its FY 2025 guidance at EPS. As a group, sell-side analysts forecast that Harrow, Inc. will post -0.53 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms have issued reports on HROW. BTIG Research increased their price objective on Harrow from $62.00 to $63.00 and gave the stock a "buy" rating in a report on Thursday, August 14th. Cantor Fitzgerald began coverage on shares of Harrow in a research note on Friday, July 11th. They issued an "overweight" rating and a $76.00 price objective on the stock. HC Wainwright raised their price objective on Harrow from $60.00 to $64.00 and gave the stock a "buy" rating in a research note on Wednesday, August 13th. Zacks Research raised Harrow from a "hold" rating to a "strong-buy" rating in a research note on Thursday, August 14th. Finally, William Blair began coverage on Harrow in a research report on Tuesday, June 10th. They set an "outperform" rating for the company. One investment analyst has rated the stock with a Strong Buy rating and seven have given a Buy rating to the company. According to data from MarketBeat.com, Harrow has a consensus rating of "Buy" and an average price target of $64.67.

Harrow Profile

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.